Equillium’s phase 3 graft-versus-host disease (GVHD) trial has missed its primary endpoint and two key secondary objectives. But the biotech brushed off the setback, highlighting other secondary ...

Incyte’s JAK1 inhibitor itacitinib has failed a key trial in graft-versus-host disease (GVHD), marking another setback for a company in need of more drug successes. The pivotal Phase 3 GRAVITAS ...

48%; P = .005) — the study’s primary endpoint — and a significantly reduced rate of moderate to severe chronic GVHD (3% vs. 33%; P = .0004) in the post-transplant cyclophosphamide group.

Belumosudil – a Rho-associated protein kinase-2 (ROCK2) inhibitor that reduces immune mediators like IL-17 and IL-23 – would be a first-in-class therapy for GVHD if approved by the FDA, says ...

The Global Graft Versus Host Disease Treatment Market was valued at USD 2.94 Billion in 2024 and is expected to reach USD 3.80 Billion by ... Graft Versus Host Disease (GVHD) is a severe medical ...

3 Chronic GvHD also tends to start with a burning rash on the same parts of the body, although it can be more severe and cause blistering, peeling, and the hardening of the skin. Gastrointestinal ...

Considering taking supplements to treat graft versus host disease gvhd? Below is a list of common natural remedies used to treat or reduce the symptoms of graft versus host disease gvhd.

ECP can be organized as a nurse-led, outpatient service similar to other apheresis-type procedures and takes 3-4 h. Initially ... ECP for the treatment of GvHD-Can We Offer Selective Immune ...

Itolizumab showed significant long-term benefits in acute GVHD, improving complete response duration and ... according to topline data from the phase 3 EQUATOR study press release from Equillium, Inc.

Hany Elmariah, MD, discusses incorporating fedratinib as maintenance therapy in the posttransplant setting to prevent relapse of MPNs and graft-vs-host disease.

High Treatment Costs High treatment costs represent one of the most significant barriers in the GVHD treatment market, as patients face substantial financial challenges. The expenses associated with ...